Hetero Labs Ltd. Unit V

Hetero Labs Ltd. Unit V is a manufacturing facility of Hetero Labs Limited, a prominent Indian pharmaceutical company. Hetero Labs Limited, often referred to as Hetero, was founded in 1989 and is headquartered in Hyderabad, India. While it is registered as a Public Limited Company, it remains privately held by its promoters and their associates. As of late 2025, the parent company had approximately 7,280 to 7,319 employees and reported a revenue of around ₹16,500 Crore (approximately $2 billion USD) for the financial year ending March 31, 2025. Its U.S. subsidiary, Hetero USA Inc., established in 2010, is based in Piscataway, New Jersey, and serves as the sales and marketing arm for APIs and Custom Pharmaceutical Services in the USA.

Hetero is a vertically integrated pharmaceutical organization engaged in research and development, manufacturing, and marketing of a wide range of chemical and biologic medicines. The company's core business areas include Active Pharmaceutical Ingredients (APIs), Global Generics, Biosimilars, and Custom Pharmaceutical Services (CDMO). It is one of the world's largest producers of APIs, particularly known for its significant role in the production of anti-retroviral (ARV) drugs for HIV/AIDS treatment, catering to an estimated 40% of the global demand. Its extensive product portfolio covers therapeutic categories such as oncology, cardiovascular, neurology, hepatitis, nephrology, and anti-hypertensives. Hetero operates over 36 manufacturing facilities globally, many of which are approved by international regulatory bodies including the USFDA and WHO.

In patent litigation, Hetero Labs Ltd. Unit V appears as an operating company, having been recorded as a defendant in one tracked case and never as a plaintiff. This posture indicates that the company primarily defends against intellectual property assertions rather than initiating them. The single case, Otsuka Pharmaceutical Co., Ltd. v. Hetero USA Inc. et al., was filed in the District of Delaware on April 4, 2014.

This notable case involves Hetero USA Inc. as a defendant, suggesting a patent dispute related to pharmaceutical products. Additionally, Hetero Labs Limited Unit V itself received a Warning Letter from the U.S. Food and Drug Administration (FDA) in 2017, citing significant violations of current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals at its Polepally Village facility in India. This historical regulatory action provides relevant context regarding the company's manufacturing operations.